Cargando…

Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat

BACKGROUND: Chronic progressive mesangioproliferative nephropathy represents a major cause of end-stage renal disease worldwide. Until now, effective approaches to stop or even slow its progression are limited. We tested the effects of an inhibitor of PDGF receptor, abl and c-kit tyrosine kinases, I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang-Rosenke, Yingrui, Khadzhynov, Dymtro, Loof, Tanja, Mika, Alice, Kawachi, Hiroshi, Neumayer, Hans-H, Peters, Harm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816310/ https://www.ncbi.nlm.nih.gov/pubmed/24119229 http://dx.doi.org/10.1186/1471-2369-14-223

Ejemplares similares

Stimulation of soluble guanylate cyclase accelerates renal recovery following relief of unilateral ureteral obstruction
por: Wang-Rosenke, Yingrui, et al.
Publicado: (2009)

IL-17 Expression in the Time Course of Acute Anti-Thy1 Glomerulonephritis
por: Loof, Tanja, et al.
Publicado: (2016)

Blood pressure-independent effects of enhanced NO/cGMP signalling and gender on aortic remodelling in experimental renal hypertension
por: Grosz, Bianca, et al.
Publicado: (2009)

Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
por: Furuto, Yoshitaka, et al.
Publicado: (2018)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

Recurrent early filter clotting in regional citrate anticoagulated continuous venovenous hemodialysis due to undetected antibodies to heparin-platelet factor 4 complexes
por: Slowinski, T, et al.
Publicado: (2010)

Pilot study on a regional citrate anticoagulated continuous venovenous hemodiafiltration protocol with variable treatment dose
por: Slowinski, T, et al.
Publicado: (2010)

Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats
por: Tauer, Josephine T., et al.
Publicado: (2015)

Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia
por: Kesely, Kristina R., et al.
Publicado: (2016)

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
por: Tanaka, Atsushi, et al.
Publicado: (2019)

Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib
por: Kim, T-M, et al.
Publicado: (2011)

The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice
por: Stephens, R Scott, et al.
Publicado: (2015)

Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
por: Ananthula, Hari Krishna, et al.
Publicado: (2018)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

Phytate Intake, Health and Disease: “Let Thy Food Be Thy Medicine and Medicine Be Thy Food”
por: Pujol, Antelm, et al.
Publicado: (2023)

Let food be thy medicine and medicine be thy food?
por: Stauss, Madelena, et al.
Publicado: (2018)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Caenorhabditis Intervention Testing Program: the tyrosine kinase inhibitor imatinib mesylate does not extend lifespan in nematodes
por: Coleman-Hulbert, Anna L., et al.
Publicado: (2019)

Thy1 marks a distinct population of slow-cycling stem cells in the mouse epidermis
por: Koren, Elle, et al.
Publicado: (2022)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib
por: Beckmann, Svenja, et al.
Publicado: (2014)

The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice
por: Reber, Laurent L., et al.
Publicado: (2017)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
por: Nteliopoulos, Georgios, et al.
Publicado: (2019)

217 Is it Idiopathic Nodular Glomerulosclerosis or Diabetic Glomerulosclerosis?
Publicado: (2022)

Thy-1+ and Thy-1- natural killer cells. Only Thy-1- natural killer cells suppress dendritic cells
Publicado: (1986)

Win Thy Heart
por: Das, Mrinal Kanti
Publicado: (2018)

Know Thy Ulcers!!!
por: Govil, Deepak, et al.
Publicado: (2020)

Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery
por: Kim, In Kyoung, et al.
Publicado: (2013)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models
por: Baek, Yi-Yong, et al.
Publicado: (2021)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Patient-reported outcomes in adequately treated hypothyroidism – insights from the German versions of ThyDQoL, ThySRQ and ThyTSQ
por: Quinque, Eva M, et al.
Publicado: (2013)

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells
por: Shi, Ping, et al.
Publicado: (2010)

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models
por: Crawford, L J, et al.
Publicado: (2014)

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2015)

Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice
por: Gergely, Péter Attila, et al.
Publicado: (2019)

Secondary Focal Segmental Glomerulosclerosis: From Podocyte Injury to Glomerulosclerosis
por: Kim, Jae Seok, et al.
Publicado: (2016)

Tyrosine kinases in rheumatoid arthritis
por: Okamoto, Hiroshi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kofat994m65n7bv3b714i5c2ra